Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Clinical Study of Gabapentin Enacarbil -Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment-

NCT01981941 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01981941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01981941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Clinical Study of Gabapentin Enacarbil -Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment-
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
November 5, 2013
Completion date
May 13, 2015
Enrollment
19 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome (rls)